

Review

Open Access

## Outcomes and quality of life following breast cancer treatment in older women: When, why, how much, and what do women want?

Jeanne Mandelblatt\*, Melissa Figueiredo and Jennifer Cullen

Address: Department of Oncology and Lombardi Cancer Center, Georgetown University, Washington, DC, USA

Email: Jeanne Mandelblatt\* - mandelbj@georgetown.edu; Melissa Figueiredo - mif2@georgetown.edu; Jennifer Cullen - jc49@georgetown.edu

\* Corresponding author

Published: 17 September 2003

Received: 30 July 2003

*Health and Quality of Life Outcomes* 2003, 1:45

Accepted: 17 September 2003

This article is available from: <http://www.hqlo.com/content/1/1/45>

© 2003 Mandelblatt et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

### Abstract

**Background:** There are few comprehensive reviews of breast cancer outcomes in older women. We synthesize data to describe key findings and gaps in knowledge about the outcomes of breast cancer in this population.

**Methods:** We reviewed research published between 1995 and June 2003 on breast cancer quality of life and outcomes among women aged 65 and older treated for breast cancer. Outcomes included communication, satisfaction, and multiple quality of life domains.

**Results:** Few randomized trials or cohort studies that measured quality of life after treatment focused exclusively on older women. Studies from older women generally noted that, with the exception of axillary dissection, type of surgical treatment generally had no effect on long-term outcomes. In contrast, the processes of care, such as choosing therapy, good patient-physician communication, receiving treatment concordant with preferences about body image, and low perceptions of bias, were associated with better quality of life and satisfaction.

**Conclusions:** With the exception of axillary dissection, the processes of care, and not the therapy itself, seem to be the most important determinants of long-term quality of life in older women.

### Introduction

Breast cancer is an important disease and one where health care services have the potential to improve the quality and quantity of life. Breast cancer is also largely a disease of old age [1,2]. By the year 2030, one in five women in the United States will be 65 years of age or older (hereinafter referred to as "older") [3]. This demographic imperative, coupled with the dramatic increases in rates of breast cancer with advancing age, is expected to translate into a large absolute increase in the number of older women treated for and surviving breast cancer [4]. These older breast cancer survivors are likely to be a phys-

iologically, socially, and racially heterogeneous group with varying numbers of comorbid conditions and varying outcomes following treatment for their disease [4,5].

Older women diagnosed with breast cancer today have many different treatment options from which to choose. While most women will choose treatments that maximize survival, information about quality of life can be an important component in decision-making in several clinical situations. For instance, if a woman is considering two treatments with equivalent survival, such as mastectomy and breast conservation, then quality of life outcomes

may be important considerations in her treatment decision-making. Likewise, in clinical trials of equivalent approaches, quality of life may be the identifying factor in determining the most "effective" treatment. Quality of life may also be important to women, providers, and researchers comparing the overall benefits of very toxic, but very effective regimens with those of less toxic approaches that yield somewhat lower survival. The balance of effectiveness, harms, and quality of life is especially important for older women, since treatment decisions must also factor in interactions of comorbid conditions and treatment.

Unfortunately, until recently, older women were not included in sizable numbers in breast cancer research. In addition, the inclusion of quality of outcomes into clinical and observation trials is also a fairly recent trend [6]. Thus, there is only limited information available on quality of life outcomes after different treatment regimens among diverse older populations. In this paper we review what is known about quality of life outcomes in older women with breast cancer. We highlight findings across multiple domains, discuss special considerations in measuring outcomes in this age group, and make some recommendations for future research. This review is intended to serve as a focal point for discussion and extension of existing efforts to improve the quality of breast cancer care for the growing older population.

## Methods

For the purposes of this review, quality of life outcomes associated with breast cancer care are defined as the net effects of the health care structure and process on the health and well-being of women diagnosed with this disease [7]. As such, quality of life is a multidimensional construct encompassing clinical, financial, functional, and psychosocial domains affected by treatment and its interactions with baseline comorbidity and circumstances (Figure 1) [6–9]. We use the term quality of life to be synonymous with the expression 'health-related quality of life' [10].

To identify relevant articles for this review, we conducted a search of published literature indexed on MedLine, CancerLit, CINAHL, and PsychInfo between 1995 and June 2003. We chose 1995 as the earliest year for review to ensure that results would be consistent with current standards of care. To capture literature encompassing a broad set of domains that might be affected by breast cancer or its treatments, we included the following terms in our searches: "breast neoplasms" and "aged" or "elderly" with "quality of life," "pain," "fatigue," "mental health," "adjustment," "body image," "satisfaction," "sexuality," "social support," "function," "communication," "cognition," or "economics." We also examined the bibliogra-

phies of retrieved articles for additional relevant citations. For citations of articles published prior to 1995, we only included sentinel articles pertinent to older women. We confined our review to original reports of randomized trials and cohort studies to examine data by age group and domain of quality of life. We excluded methodological articles, reviews, case series, and case reports, and non-English language articles. Articles were reviewed for inclusion of older women and data were abstracted on post-treatment quality of life or other outcomes for this age group. It should be noted that most observational studies to date have only examined short-term side effects and symptoms of treatment and future research is need on long-term side effects of treatments in older breast cancer survivors. We confine citations of data to results that were statistically significant, highlighting findings that are controlled for key confounding variables, such as baseline functioning [11]. We present a qualitative summary of these results. We did not attempt to conduct a meta-analysis of results since each study was conducted using varying time horizons, used different measurement tools and definitions of quality of life domains, included heterogeneous populations with a variety of tumor stages, and was conducted in different countries and cultural perspectives.


## Results

Overall, few randomized trials or cohort studies measured quality of life after treatment and focused exclusively on older women [12–14]. With rare exceptions, [15–17] studies involving breast cancer outcomes were conducted in non-minority populations.

### Processes of Care and Satisfaction

Satisfaction with breast cancer treatment is primarily a function of the process of care, and not the actual treatment received. A summary of these processes of care issues is found in Table 1. As one example, women who felt their surgeons initiated a conversation about treatment concerns reported higher satisfaction six months post-treatment than women who felt their surgeons communicated less, controlling for treatment and other factors [18]. Of note, surgeons who received additional training in surgical oncology have been noted by their older patients to bring up a discussion about patient concerns 60% more often (95% CI 1.02–2.56) than surgeons without specialty training [18].

Older patients may prefer and rely on physician-initiated quality of life discussions [19] and may prefer that their physicians provide information in person as opposed to written materials [20]. Higher levels of communication, both physician and patient-initiated, also affect women's perceptions of having a choice of treatment. For instance, in one study, older women who reported that their physicians asked them caring questions, asked about their con-



Adapted (in part) from Buchner and Wagner, 1992[98] and Mandelblatt, Bierman, et al. 1999[5]

**Figure 1**  
Conceptual Model of Quality of Life in Older Breast Cancer Patients

**Table 1: Key issues in processes of care in older breast cancer patients**

Issue	Comment
Communication	<ul style="list-style-type: none"> <li>Physician-initiated communication and shared-decision making related to increased satisfaction</li> <li>Increased communication related to increased perception of choice</li> </ul>
Perceptions of ageism	<ul style="list-style-type: none"> <li>Higher levels of perceived ageism related to decreased satisfaction with care</li> <li>Higher levels of perceived ageism related to higher levels of self-reported pain</li> </ul>
Setting of care	<ul style="list-style-type: none"> <li>In-patient rehabilitation or case management may improve outcomes in women with multiple comorbidities</li> </ul>
Social support	<ul style="list-style-type: none"> <li>Inadequate social support associated with less satisfaction with care</li> </ul>
Preferences for treatment	<ul style="list-style-type: none"> <li>Concordance between preference for appearance and type of surgical treatment related to better mental health</li> </ul>

cerns, or who discussed a number of options were more than twice as likely to report that they felt they were given a choice of treatment, controlling for other factors [18].

Interestingly, there appears to be a positive health benefit to having had a choice per se. In one cohort, by six months after surgery, women who reported having had a choice of therapy also reported higher adjusted global

health on a linear rating scale than women who felt they had no choice (78.7 vs. 75.3 on a zero to 100 scale,  $p = .03$ ) [21]. Women reporting a choice also felt more satisfied with their treatments than women who reported having no choice, considering other factors. Other investigators have also noted that women who share in the decision-making process are more likely to report being satisfied, have better post-treatment adjustment to cancer, than women who feel that they did not participate [9,22–25]. Of note, in one longitudinal cohort, older women who received treatment that was consistent with their preferences around body image reported better mental health at follow-up than those who received surgery that was inconsistent with their preferences (e.g., receiving mastectomy without reconstruction despite a concern about maintaining body image) [26]. Interventions to facilitate decision-making that is consistent with preferences, such as CD-ROM programs, appear to have the potential to improve satisfaction with treatment decisions and with interactions with health care providers, as well as increase overall self-reported health and physical functioning [27].

Other features of women's interactions with the medical care system appear to be significant predictors of satisfaction, including perceptions of ageism ( $p = .01$ ) and racism ( $p = .03$ ) [16]. For example, women who perceive high levels of ageism have reported less general satisfaction with their breast cancer care than women who felt there was less ageism in their interactions in the health care system.

The setting of care may also influence outcomes. For instance, for older women with multiple comorbid illnesses (>3), in-patient rehabilitation has been noted to improve multiple domains of quality of life, and many of these effects appeared to be maintained after discharge [28]. Similarly, intensive nurse case management programs have been found to improve mood and reduce feelings of uncertainty [29].

Experiences outside of the health care system, such as having less social support, have also been associated with being less satisfied with one's breast cancer care [13]. In addition, Silliman and colleagues found that older women with inadequate social support had poor psychosocial outcomes after breast cancer treatment [30].

#### **Preferences for Treatment**

In the studies conducted to date, older patients are able to state their preferences, and generally want to be fully informed about their treatment options [31–34]. Preferences are important considerations in treatment choices [35]. For example, in two studies, older breast cancer patients were willing to select a risky treatment option (chemotherapy with major toxicity) for a small increase in


life expectancy (e.g., 6 months) [31,36]. In another study, 80% of older women indicated that chemotherapy would be worthwhile if they could live an additional two years,[37] but others have found that women in this age group would accept aggressive chemotherapy for as little as a 1% increase in survival [38,39]. Overall, these results suggest that older women are willing to trade-off short-term physical well-being, such as occurs with chemotherapy, for increased survival.

#### **Physical Function and Pain**

While many have hypothesized that breast conservation will result in better post-treatment functioning than mastectomy, in reviewing the literature we found that adjusted physical function scores were not significantly different by treatment group, [12] but rather, largely related to women's general pre-morbid level of illness [16,17,40–43].

The physical function outcome of treatment relates to use of axillary node dissection [44]. In one series, the cumulative risk of having arm problems two years post-treatment were three times higher (95% CI 1.94–4.67) among women who underwent axillary surgery compared to women without axillary surgery, controlling for covariates. Arm problems after axillary dissection were reported by up to 60% of women and had a consistent negative impact on long-term functional abilities [16]. Of note, one study reported that the effects of having axillary dissection and arthritis were multiplicative two years post-surgery (Figure 2) [45]. The expected benefit of having fewer concerns about recurrence after axillary dissection has not been demonstrated [16]. Using a decision analytic approach, Parmigiani and colleagues also noted that axillary dissection had an overall negative impact on the quality-adjusted survival of 60-year-old women [46]. Other researchers have noted that long-term decrements in physical function can affect activities of daily living that are critical to an older woman's ability to live independently [42,43]. Thus, in a Medicare population, the risks of axillary surgery may outweigh any benefits in guiding adjuvant therapy or of more detailed knowledge of prognosis [47–56]. Sentinel node biopsy has been shown to have lower morbidity than axillary dissection, [57] and may be particularly useful in older patients, especially those with arthritis or other pre-existing mobility limitations [58]. Final conclusions about the value of axillary dissection will rest on the accuracy of sentinel biopsy and women's preferences.

Radiation has not been found to increase pain or affect quality of life (measured on the EORTC breast module) in older women participating in clinical trials [14]. For older women undergoing chemotherapy, quality-adjusted benefits are similar to those seen in younger women when



**Figure 2**  
Percent of older women reporting arm problems after axillary dissection: Relationship to presence of arthritis.

considering women with estrogen receptor negative tumors. For older women with estrogen positive disease, quality adjusted survival is significantly improved with chemotherapy, albeit at a somewhat lower level than seen in younger women [59].

The process of care also seems to affect physical outcomes. For instance, Mandelblatt and colleagues found that older women who perceived high levels of ageism (vs. lower levels) in the health care system or felt that they had no choice of treatment (vs. having a choice) reported significantly more bodily pain [13].

**Symptoms**

Symptoms, such as hot flashes on tamoxifen treatment, have been noted to decrease general quality of life in older women, either directly, or through associated disturbed sleep and fatigue [60]. Fatigue from treatment, especially

in association with pain or other symptoms, can increase anxiety and depression [61]. In a cross-sectional study of 841 older patients, pain, fatigue, and insomnia were significantly related to losses in physical functioning, even after controlling for cancer treatment and comorbid conditions [62]. In a one-year follow-up of the same cohort, chemotherapy was related to reports of fatigue in the short-term, but not at one-year post-treatment [63]. A recent randomized controlled trial of exercise training[64] suggests that overall quality of life, as measured by the FACT-B scale, increases significantly in the postmenopausal breast cancer survivors who exercise regularly. Reductions in fatigue and improvements in mood were also reported, indicating that further testing of exercise interventions in older breast cancer survivors is warranted.

**Mental Health and Overall Impact**

The processes of care, including feeling like one had a choice of treatment also are important predictors of health outcomes. For example, in one cohort of older women, choice was independently associated with reports of better mental health [13]. Recently, Keating and colleagues extended these results and demonstrated that the concordance between desired and actual decision-making was actually more important than the actual process itself [65].

Receipt of chemotherapy (yes vs. no) has not been related to any long-term mental health outcomes except for having a perception that breast cancer had a greater impact on one's life, even after considering stage and other factors [13]. One aspect of this negative impact has been distress about weight gain associated with chemotherapy [66].

Interestingly, better educated women report that breast cancer has a greater impact on their lives than their less well educated counterparts, but the oldest women (75+ years) rate breast cancer as having less of an impact on their lives than younger women (67 to 74 years) [13]. The experience of having breast cancer has also been noted to have positive effects on women's lives, [67] and feeling a sense of purpose in life has been found to have a greater impact on quality of life than breast cancer itself [67].

Interestingly, older women are less likely to use mental health (or alternative medicine) services than younger patients [68]. However, participation in mental health support, such as performing expressive journaling has been found to improve short-term (i.e., 3 months) mental health outcomes and vitality and to decrease the number of medical appointments for cancer-related symptoms [69].

**Cognition**

Patients with breast cancer frequently complain of problems with their memory and concentration. Such reports are known colloquially as "chemobrain" or "chemofog" <http://www.pinkribbon.com/chemobr.htm>. Empirical evidence is accumulating that cognitive problems are associated with use of surgery and chemotherapy (e.g., Ahles et al, 2002) [70]. For example, Cimprich [71] examined attention and reported decrements in attention-related tasks in older, but not in younger breast cancer patients. Tamoxifen has also been found to negatively affect cognition [72] in a sample of women aged 57-75.

As cognitive problems interact with fatigue, pain, depression, and sleep quality in their impact on functioning, interventions to improve cognition (and/or reduce these other symptoms) could lead to improvements in other domains. Cognitive behavior therapy has been found to

be effective in improving sleep, cognition, and quality of life in younger groups [73] and such interventions could be expanded to include older women. Examination of long-term cognitive effects of adjuvant treatment using validated neuropsychological batteries and evaluation of fatigue prior to and after surgery and adjuvant therapy is warranted. Improving cognition may also have long-term effects on survival, since impaired cognitive status has been associated with poorer survival, controlling for age, stage, and treatment [41].

**Body Image and Sexuality**

In the multi-center EORTC trial of mastectomy versus breast conservation (plus tamoxifen) there was a trend towards better body image one year after treatment among women 70 years and older [12]. In other studies, older women undergoing breast conservation have reported better body image (and mental health) two-years post-treatment compared to the women who had undergone mastectomy, [26,74] although results have been inconsistent [75,76]. National estimates of breast reconstruction rates following mastectomy demonstrate lower use among older women, with only 1.3% to 4.1% of women over age 70 having reconstruction compared to 17.9% of younger women [77,78].

There is a paucity of data on sexual feelings and outcomes in older women with breast cancer. In our own research, we observed that 15.1% of women had been sexually active prior to breast cancer diagnosis and that many women reported that breast cancer had either a "very negative" or "somewhat negative" impact on their sexual feelings and interest (Mandelblatt, unpublished data, 2003).

**Social and Role Function**

Social and role functions are inextricably linked to social support and integration prior to breast cancer diagnosis. Breast cancer survivors who are more socially integrated before their breast cancers report better post-treatment role function and vitality than less socially integrated women [79]. In fact, Michael and colleagues report that social integration accounts for greater variance in quality of life than treatment itself [79]. As a result, others have developed social support interventions targeted to breast cancer survivors with poor support systems. In a recent randomized, prospective trial, the quality of life of older women improved when communicating with a community-based nurse case manager who provided help with managing comorbid conditions, assistance with activities of daily living (ADLs), and help navigating the health care system [80]. Similarly, Silliman and colleagues [30] found that older women relied heavily on their physicians for support and they suggest enhanced physician-patient communication may improve emotional health outcomes in these women. With intense support, women

generally report better well-being and lower distress, [81] although some studies have not been able to demonstrate this effect [82].

### **Economic Outcomes**

Breast cancer accounted for between one-fifth and one-quarter of the \$157 billion dollars in cancer costs in the United States in 2001 [83]. Lower costs per woman have been reported for older women compared to costs for younger women [84] and is probably partly explained by less aggressive treatment offered to older women [35]. Interestingly, economic market forces affect costs and patterns of care in older women. For example, Hadley and colleagues examined Medicare claims and demonstrated that women living in areas with the highest ratio of mastectomy fees relative to breast conservation fees were significantly more likely to have mastectomy, while women in areas where there was less of a fee differential between the two procedures were most likely to get breast conservation [85].

In one economic analysis spanning a five year horizon after breast cancer treatment, Polsky and colleagues found that the initial costs of six weeks of radiation makes breast conservation more expensive than mastectomy, with no significant differences in quality-adjusted survival. Summing costs and outcomes over five years post-treatment, breast conservation and radiation cost more than \$200,000 per quality adjusted life year saved (QALY) compared to mastectomy. In an alternative formulation, where breast conservation and radiation are compared to open choice, and choice is assumed to have a utility in and of itself (as noted above), the cost-effectiveness ratio for breast conservation drops to as low as approximately \$50,000 to \$75,000 per QALY, well within the threshold for current medical expenditures [86].

### **Caregiver Burden**

There is a paucity of data about the impact of breast cancer in older women on their family members and caregivers. Female gender, older age, and past grief experiences have been associated with increased distress and grief in spousal caregivers of cancer patients [87]. In one study, daughters and sisters of women with breast cancer perceived that their information and support needs were not well met [88]. In another report, Northouse and colleagues found that family members of patients with recurrent disease experienced decrements in emotional well being, and that negative impact was mediated by family hardness and social support [89]. Among caregivers of a small sample of cancer patients sleep problems predicted 63.6% of the variance in caregiver depression [90]. Since older women are likely to be primary caregivers for their spouses or grandchildren, when they are undergoing breast cancer treatment or terminally ill, caregiver burden

is compounded by loss of this key family resource. Overall, more research is needed to assess caregiver needs and develop appropriate interventions geared to older patients and their families.

### **Special Considerations in Quality of Life Measurement**

To date, quality of life assessments in older women have employed a wide variety of methods and tools to assess outcome. Some limitations of prior evaluations include use of a limited number of domains, lack of standard agreement on the appropriate comparison groups (e.g., other cancer patients, women without cancer) or failure to compare results to any control group, and inclusion of narrow segments of the breast cancer population (e.g., only well-educated, non-minority women). Furthermore, few prior studies were designed to specifically evaluate outcomes for older women, particularly to assess the interactions of decrements in function or well being associated with treatment with comorbid conditions. For example, mild treatment related peripheral neuropathy might significantly impair ambulation in an older diabetic woman with pre-existing neuropathic changes. Visual problems associated with tamoxifen could be especially detrimental to older women with underlying visual impairment. Lack of control for baseline function may also over-estimate the magnitude of treatment-related decrements in quality of life.

Certain domains of quality of life may be more salient to older women than other groups of breast cancer patients. For instance, for older women, ambulation and mobility impairments may make the difference between independent living and assisted living [43,91]. Likewise, mild fatigue may have a multiplicative effect in impairing activities of daily living in a frail older woman, while only being bothersome to a younger woman. Presence of comorbid conditions may also limit discussion of treatment options [92] or complicate delivery of treatment such as chemotherapy [40,93,94]. Conversely, it is important to recognize heterogeneity in elderly women such that special subsets will have few chronic diseases and greater functional status; such patients will be able to tolerate more intensive therapy (i.e. "fit elderly") [95].

Administration of quality of life evaluations for older patients may also be difficult and can compromise the quality of data obtained. For instance, visual or hearing problems may lead to miscomprehension of survey items, and memory impairments may lead to obtaining inaccurate data, especially about more distal events. Older women also may telescope time and discount the importance of health events that are in the future versus those in the present.

**Table 2: Recommendations for Future Research with Older Breast Cancer Patients**

Area of research	Recommendations
Methodological issues	<ul style="list-style-type: none"> <li>• Long-term follow-up needed</li> <li>• Increase sample sizes</li> </ul>
Body image and sexuality	<ul style="list-style-type: none"> <li>• Integrate quality of outcomes into clinical and observation trials</li> <li>• Include reliable and valid measures of body image and sexuality concerns</li> <li>• Discuss preferences</li> </ul>
Effects of comorbid conditions	<ul style="list-style-type: none"> <li>• Design studies to specifically evaluate interactions of decrements in function or well being associated with treatment of comorbid conditions.</li> <li>• Use of multiple informants approach with cognitively impaired women [96]</li> <li>• Use of Comprehensive Prognostic Index [97]</li> </ul>
Cognitive effects of treatments and evaluation of fatigue	<ul style="list-style-type: none"> <li>• Examine long-term cognitive effects of adjuvant treatment using validated neuropsychological batteries</li> </ul>
Interventions to improve quality of life	<ul style="list-style-type: none"> <li>• Evaluate fatigue prior to and after surgery, and adjuvant therapy</li> <li>• Educate medical staff on older women's unique concerns and needs</li> <li>• Develop interventions to improve patient-physician communication</li> <li>• Use decision aides to elicit preferences and enhance shared decision making</li> <li>• Tailor interventions to account for cultural factors</li> </ul>
Caregiver burden	<ul style="list-style-type: none"> <li>• Examine caregiver sleep problems and their role in depression</li> <li>• Increase social support</li> <li>• Assess quality of the dying experience for patient and caregiver</li> <li>• Test models to relieve caregiver burden</li> </ul>

Thus, as indicated by the pathways depicted in Figure 1, consideration of comorbidity data is essential for future outcomes research among older women. Exclusion of older women with multiple comorbidities from clinical trials may result in less representative samples of breast cancer patients and interfere with improving understanding of the impact that such conditions have on quality of life. Specialized tools and methodologies may need to be developed and applied to research with older female populations to fully capture non-cancer influences on outcomes. Examples could include the multiple informants approach when working with cognitively impaired women [96] or the Comprehensive Prognostic Index [97] which is created by combining indices of comorbidities that impact breast cancer survival with age and cancer stage.

Thus, there are many methodological challenges inherent in working with older populations. Researchers interested in studying older women's quality of life will need to be cognizant of these special issues to ensure high quality results. Further research is necessary to ensure that we are using the proper approaches to obtain valid information and to improve the quality of care for older women.

#### Future Directions

This review is intended to highlight key outcomes among older women surviving breast cancer. Our results can be used to inform clinical decision-making and design interventions to improve quality of care and optimize func-

tioning in this growing population (Table 2). Additional research is needed to understand dynamic interactions between cancer survivorship, comorbidities, aging per se, poverty, ethnicity, and the processes of interaction with the medical care system in producing the observed outcomes of care.

#### Acknowledgements

The authors would like to thank Trina McClendon for manuscript preparation. This review is dedicated to the memory of Natalie Davis Springarn: your example of living and dying gracefully with breast cancer give us hope and guide our work.

#### References

1. National Cancer Institute: **SEER Cancer Statistics Review 1973-1995. Specific data from NCHS Public Use Tape.** Edited by: Ries LAG, Kosary CL, Hankey BF, Miller BA and Edwards BK. Bethesda, MD; 1998.
2. National Cancer Institute DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April: **Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1998).** 2001.
3. BJ Soldo and EM Agree: **America's elderly.** Washington, DC, Population Reference Bureau, Inc.; 1988.
4. TL Lash and RA Silliman: **Prevalence of cancer.** *J Natl Cancer Inst* 1998, **90**:399-400.
5. JS Mandelblatt, AS Bierman, K Gold, Y Zhang and al et: **Constructs of burden of illness in elderly breast cancer patients: A comparison of measurement methods.** *Health Serv Res* 1999, **36**:1085-1107.
6. JS Mandelblatt and JM Eisenberg: **Historical and methodological perspectives on cancer outcomes research.** *Oncology (Huntingt)* 1995, **9**:23-32.
7. DL Patrick and P Erickson: **Health status and health policy.** *Quality of Life in Health Care Evaluation and Resource* 1993.
8. MF Drummond, GL Stoddard and GW Torrance: *Methods for the Economic Evaluation of Health Care programmes.* New York, NY, Oxford University Press; 1987.



9. LJ Fallowfield, A Hall, GP Maguire and M Baum: **Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial.** *Br Med J* 1990, **301**:575-580.
10. PA. Ganz: **Quality of life measures in cancer chemotherapy, methodology and implications.** *Pharmacoecon* 1994, **5**:376-388.
11. Bottomley A and Therasse P: **Quality of life in patients undergoing systemic therapy for advanced breast cancer.** *Lancet Oncol* 2002, **3**:620-628.
12. de Haes JC, Curran D, Aaronson NK and Fentiman IS: **Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial.** *Eur J Cancer* 2003, **39**:945-951.
13. J Mandelblatt, S.B Edge, NJ Meropol, R. Senie, T Tsangaris, L Grey and al. et: **Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care.** *J Clin Oncol* 2003, **21**:855-863.
14. Rayan G, Dawson LA, Bezjak A, Lau A, Fyles AW, Yi QL, Merante P and Vallis KA: **Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy.** *Int J Radiat Oncol Biol Phys* 2003, **55**:154-161.
15. Gotay CC, Holup JL and Pagano I: **Ethnic differences in quality of life among early breast and prostate cancer survivors.** *Psychooncology* 2002, **11**:103-113.
16. J Mandelblatt: **Variations In Breast Cancer Treatment in Older Medicare Beneficiaries: Is it black or white?** *Cancer* 2002.
17. K Ashing-Giwa, PA Ganz and L Petersen: **Quality of life of African-American and white long term breast carcinoma survivors.** *Cancer* 1999, **85**:418-426.
18. Liang W, C Burnett, JH Rowland, NJ Meropol, L Eggert, YT Hwang and al. et: **Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction.** *J Clin Oncol* 2002, **20**:1008-1016.
19. Detmar SB, Aaronson NK, Wever LD, Muller M and Schornagel JH: **How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues.** *J Clin Oncol* 2000, **18**:3295-3301.
20. Maly RC, Leake B and Silliman RA: **Health care disparities in older patients with breast carcinoma: informational support from physicians.** *Cancer* 2003, **97**:1517-1527.
21. D Polsky, N Keating, J Weeks and K Schulman: **Patient Choice of Breast Cancer Treatment: Impact on health state preferences.** *Med Care* 2002.
22. J Morris and R Ingham: **Choice of surgery for early breast cancer: Psychosocial considerations.** *Soc Science & Med* 1988, **27**:1257-1262.
23. BR Cassileth, RV Zupkis, K Sutton-Smith and al et: **Information and participation preferences among cancer patients.** *Ann Intern Med* 1980, **92**:832-836.
24. J Morris, GT Royle and I Taylor: **Changes in the surgical management of early breast cancer in England.** *J Royal Soc Med* 1989, **82**:12-14.
25. A Liberati, G Apolone, A Nicolucci, C Confalonieri, R Fossati, R Grilli and al et: **The role of attitudes, beliefs, and personal characteristics of Italian physicians in the surgical treatment of early breast cancer.** *Am J Pub Health* 1991, **81**:38-42.
26. MI Figueiredo, J Cullen, YT Hwang and JS Mandelblatt: **Body image and emotional well-being in older women with breast cancer.** Edited by: *24th Annual Society of Behavioral Medicine Meeting. Salt Lake City, UT*; 2003.
27. Molenaar S, Sprangers MA, Rutgers EJ, Luiten EJ, Mulder J, Bossuyt PM, van Everdingen JJ, Oosterveld P and de Haes HC: **Decision support for patients with early-stage breast cancer: effects of an interactive breast cancer CDROM on treatment decision, satisfaction, and quality of life.** *J Clin Oncol* 2001, **19**:1676-1687.
28. ME Heim, S Kunert and I. Ozkan: **Effects of impatient rehabilitation on health-related quality of life in breast cancer patients.** *Onkologie* 2001, **24**:268-272.
29. Ritz LJ, Nissen MJ, Swenson KK, Farrell JB, Sperduto PV, Sladek ML, Lally RM and Schroeder LM: **Effects of advanced nursing care on quality of life and cost outcomes of women diagnosed with breast cancer.** *Oncol Nurs Forum* 2000, **27**:923-932.
30. RA Silliman, KA Dukes, LM Sullivan and SH Kaplan: **Breast cancer care in older women: Sources of information, social support, and emotional health outcomes.** *Cancer* 1998, **83**:706-711.
31. RP McQuellon, HB Muss, SL Hoffman, G Russell and al et: **Patient preferences for treatment of metastatic breast cancer: A study of women with early-stage breast cancer.** *J Clin Oncol* 1995, **13**:858-868.
32. Llewellyn-Thomas HA, Sutherland HJ, Tritchler DL, Lockwood GA, Till JE, Ciampi A, Scott JF, Lickley LA and Fish EB: **Benign and malignant breast disease: the relationship between women's health status and health values.** *Med Decis Making* 1991, **11**:180-188.
33. Bj McNeil, SG Pauker, Jr. Sox HC and A Tversky: **On the elicitation of preferences for alternative therapies.** *N Engl J Med* 1982, **306**:1259-1262.
34. Till JE, Sutherland HJ and Meslin EM: **Is there a role for preference assessments in research on quality of life in oncology?** *Qual Life Res* 1992, **1**:31-40.
35. JS Mandelblatt, J Hadley, J Kerner, K Schulman and al et: **Patterns of breast cancer treatment in the elderly: Patient, physician, and medical system influences.** 1999.
36. SB Yellen and DF Cella: **Someone to live for: Social well-being, parenthood status, and decision-making in oncology.** *J Clin Oncol* 1995, **13**:1255-1264.
37. RJ Simes, K Cocker, P Glasziou and al et: **Costs and benefits of adjuvant chemotherapy for breast cancer: An assessment of patient preferences.** *Proc Am Soc Clin Oncol* 1989, **8**:52.
38. ML Slevin, L Stubbs, HJ Plant and al et: **Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses and general public.** *BMJ* 1990, **300**:1458-1460.
39. PM Ravdin, IA Siminoff and JA Harvey: **Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.** *J Clin Oncol* 1998, **16**:515-521.
40. Newschaffer CJ, Penberthy L, Desch CE, Retchin SM and Whittemore M: **The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer.** *Arch Intern Med* 1996, **156**:85-90.
41. JS Goodwin, JM Samet and WC Hunt: **Determinants of survival in older cancer patients.** *J Natl Cancer Inst* 1996, **88**:1031-1038.
42. WA Satariano, DR Ragland and GN DeLorenze: **Limitations in upper-body strength associated with breast cancer: a comparison of black and white women.** *J Clin Epidemiol* 1996, **49**:535-44.
43. RA Silliman, MN Prout, T Field and et al: **Risk factors for a decline in upper body function following the treatment for early stage breast cancer.** *Breast Cancer Res Treat* 1999, **54**:25-30.
44. Beaulac SM, McNair LA, Scott TE, LaMorte WW and Kavanah MT: **Lymphedema and quality of life in survivors of early-stage breast cancer.** *Arch Surg* 2002, **137**:1253-1257.
45. J Mandelblatt, S Edge, N Meropol, R Senie, T Tsangaris, L Grey and al. et: **Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma.** *Cancer* 2002, **95**:2445-2454.
46. G Parmigiani, DA Berry, EP Winer, C Tebaldi, JD Iglehart and LR Prosnitz: **Is axillary lymph node dissection indicated for early-stage breast cancer? a decision analysis.** *J Clin Oncol* 1999, **17**:1465-73.
47. E Maunsell, J Brisson and L Deschenes: **Arm problems and psychological distress after surgery for breast cancer.** *Can J Surg* 1993, **36**:315-320.
48. MW Kissin, GQ Della Rovere, D Easton and G Westbury: **Risk of lymphoedema following treatment of breast cancer.** *Br J Surg* 1986, **73**:580-584.
49. Vevers JM Roumen RM and Vingerhoets AJ Vrengdenhil G, Coebergh JW, Crommelin MA, et al: **Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer.** *Eur J Cancer* 2001, **37**:991-999.
50. V Velanovich: **Axillary Lymph Node Dissection for Breast Cancer: A decision analysis of T1 lesions.** *Annals of Surgical Oncology* 1997, **5**:131-139.
51. B Cady: **Is axillary lymph node dissection necessary in routine management of breast cancer? No.** *Important Advances in Oncology* 1996:251-265.
52. P Goss, T Hack, L Cohen, P Ritvo and J Katz: **Long term physical and psychological morbidity of axillary lymph node dissection (ALND) in patients with breast cancer.** *Proc Am Soc Clin Oncol* 1996, **15**:123.
53. MA Warmuth, G Bowen, LR Prosnitz, L Chu, G Broadwater, B Peterson, G Leight and EP Winer: **Complications of axillary lymph**

- node dissection for carcinoma of the breast: A report based on a patient survey.** *Cancer* 1998, **83**:1362-1368.
54. D Ivens, AL Hoe, TJ Podd, CR Hamilton, I Taylor and GT Royle: **Assessment of morbidity from complete axillary dissection.** *Br J Cancer* 1992, **66**:136-138.
  55. TF Hack, L Cohen, J Katz, LS Robson and P Goss: **Physical and psychological morbidity after axillary lymph node dissection for breast cancer.** *J Clin Oncol* 1999, **17**:142-149.
  56. Kuehn T, Klauss W, Darsow M, Regele S, Flock F, Maiterth C, Dahlbender R, Wendt I and Kreienberg R: **Long-term morbidity following axillary dissection in breast cancer patients--clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors.** *Breast Cancer Res Treat* 2000, **64**:275-286.
  57. Swenson KK, Nissen MJ, Ceronosky C, Swenson L, Lee MW and Tuttle TM: **Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer.** *Ann Surg Oncol* 2002, **9**:745-753.
  58. Schijven MP, Vingerhoets AJ, Rutten HJ, Nieuwenhuijzen GA, Roumen RM, van Bussel ME and Voogd AC: **Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy.** *Eur J Surg Oncol* 2003, **29**:341-350.
  59. Cole BF, Gelber RD, Gelber S, Coates AS and Goldhirsch A: **Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.** *Lancet* 2001, **358**:277-286.
  60. Stein KD, Jacobsen PB, Hann DM, Greenberg H and Lyman G: **Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer.** *J Pain Symptom Manage* 2000, **19**:436-445.
  61. Stone P, Richards M, A'Hern R and Hardy J: **A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer.** *Ann Oncol* 2000, **11**:561-567.
  62. Given B, Given C, Azzouz F and Stommel M: **Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment.** *Nurs Res* 2001, **50**:222-232.
  63. Given CW, Given B, Azzouz F, Kozachik S and Stommel M: **Predictors of pain and fatigue in the year following diagnosis among elderly cancer patients.** *J Pain Symptom Manage* 2001, **21**:456-466.
  64. KS Courtney, JR Mackey, GJ Bell, LW Jones, CJ Field and AS Fairey: **Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: Cardipulmonary and quality of life outcomes.** *JCO* 2003, **21**:1660-1668.
  65. N Keating, E Guadagnoli, M Landrum, C Borbas and J Weeks: **Patients participation in treatment decision making: Should Physicians match patients desired levels of involvement?** *J Clin Oncol* 2002, **20**:1473-1479.
  66. McInnes JA and Knobf MT: **Weight gain and quality of life in women treated with adjuvant chemotherapy for early-stage breast cancer.** *Oncol Nurs Forum* 2001, **28**:675-684.
  67. Tomich PL and Helgeson VS: **Five years later: a cross-sectional comparison of breast cancer survivors with healthy women.** *Psychooncology* 2002, **11**:154-169.
  68. Patterson RE, Neuhofer ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ and Marshall LM: **Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs.** *J Altern Complement Med* 2002, **8**:477-485.
  69. Stanton AL, Danoff-Burg S, Cameron CL, Bishop M, Collins CA, Kirk SB, Sworowski LA and Twillman R: **Emotionally expressive coping predicts psychological and physical adjustment to breast cancer.** *J Consult Clin Psychol* 2000, **68**:875-882.
  70. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER and Silberfarb PM: **Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.** *J Clin Oncol* 2002, **20**:485-493.
  71. Cimprich B: **Age and extent of surgery affect attention in women treated for breast cancer.** *Res Nurs Health* 1998, **21**:229-238.
  72. Paganini-Hill A and Clark LJ: **Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen.** *Breast Cancer Res Treat* 2000, **64**:165-176.
  73. Quesnel C, Savard J, Simard S, Ivers H and Morin CM: **Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer.** *J Consult Clin Psychol* 2003, **71**:189-200.
  74. Amichetti M and Caffo O: **Quality of life in patients with early stage breast carcinoma treated with conservation surgery and radiotherapy. An Italian monoinstitutional study.** *Tumori* 2001, **87**:78-84.
  75. Nissen MJ, Swenson KK, Ritz LJ, Farrell JB, Sladek ML and Lally RM: **Quality of life after breast carcinoma surgery: a comparison of three surgical procedures.** *Cancer* 2001, **91**:1238-1246.
  76. Cohen L, Hack TF, de Moor C, Katz J and Goss PE: **The effects of type of surgery and time on psychological adjustment in women after breast cancer treatment.** *Ann Surg Oncol* 2000, **7**:427-434.
  77. Morrow M, Scott SK, Menck HR, Mustoe TA and Winchester DP: **Factors influencing the use of breast reconstruction post-mastectomy: a National Cancer Database study.** *J Am Coll Surg* 2001, **192**:1-8.
  78. Alderman AK, McMahon L, Jr. and Wilkins EG: **The national utilization of immediate and early delayed breast reconstruction and the effect of sociodemographic factors.** *Plast Reconstr Surg* 2003, **111**:695-703.
  79. Michael YL, Berkman LF, Colditz GA, Holmes MD and Kawachi I: **Social networks and health-related quality of life in breast cancer survivors: a prospective study.** *J Psychosom Res* 2002, **52**:285-293.
  80. A Jennings-Sanders and ET. Anderson: **Older women with breast cancer perceptions of the effectiveness of nurse case managers.** *Nursing Outlook* 2003, **51**:108-114.
  81. Kornblith AB, Herndon JE, Zuckerman E, Viscoli CM, Horwitz RJ, Cooper MR, Harris L, Tkaczuk KH, Perry MC, Budman D, Norton LC and Holland J: **Social support as a buffer to the psychological impact of stressful life events in women with breast cancer.** *Cancer* 2001, **91**:443-454.
  82. Sandgren AK, McCaul KD, King B, O'Donnell S and Foreman G: **Telephone therapy for patients with breast cancer.** *Oncol Nurs Forum* 2000, **27**:683-688.
  83. Radice D and Redaelli A: **Breast cancer management: quality-of-life and cost considerations.** *Pharmacoeconomics* 2003, **21**:383-396.
  84. WE Barlow, SH Taplin, CK Yoshida, DS Buist, D Seger and M Brown: **Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer.** *J Natl Cancer Inst* 2001, **93**:447-455.
  85. J Hadley, J Mandelblatt, JM Mitchell, JC Weeks, E Guadagnoli, YT Hwang and al. et: **Medicare breast surgery fees and treatment received by older women with localized breast cancer.** *Health Serv Res* 2003, **38**:553-573.
  86. Polsky D, Glick HA, Willke R and Schulman K: **Confidence intervals for cost-effectiveness ratios: a comparison of four methods.** *Health Econ* 1997, **6**:243-252.
  87. O Gilbar and H. Ben-Zur: **Bereavement of spouse caregivers of cancer patients.** *American Journal of Orthopsychiatry* 2002, **72**:422-432.
  88. K Chalmers, S Marles, D Tataryn, S Scott-Findlay and K. Serfas: **Reports of information and support needs of daughters and sisters of women with breast cancer.** *Eur J Cancer Care* 2003, **12**:81-90.
  89. Northouse LL, Mood D, Kershaw T, Schafenacker A, Mellon S, Walker J, Galvin E and Decker V: **Quality of life of women with recurrent breast cancer and their family members.** *J Clin Oncol* 2002, **20**:4050-4064.
  90. PA Carter and BL. Chang: **Sleep and depression in cancer caregivers.** *Cancer Nursing* 2000, **23**:410-415.
  91. WA Satariano and DR Ragland: **Upper-body strength and breast cancer: a comparison of the effects of age and disease.** *J Gerontol A Biol Sci Med Sci* 1996, **51**:M215-9.
  92. Velanovich V, Gabel M, Walker EM, Doyle TJ, O'Bryan RM, Szymanski W, Ferrara JJ and Lewis F.R., Jr.: **Causes for the undertreatment of elderly breast cancer patients: tailoring treatments to individual patients.** *J Am Coll Surg* 2002, **194**:8-13.
  93. R Yancik, MN Wesley, LA Ries, RJ Havlik, BK Edwards and JW Yates: **Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older.** *JAMA* 2001, **285**:885-892.
  94. Blackman SB, Lash TL, Fink AK, Ganz PA and Silliman RA: **Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients.** *Cancer* 2002, **95**:2465-2472.

95. Firat S, Gore E and Byhardt RW: **Do "elderly fit" patients have less comorbidity?** *Int J Radiat Oncol Biol Phys* 2003, **55**:1166-1168.
96. Lash TL, Thwin SS, Horton NJ, Guadagnoli E and Silliman RA: **Multiple informants: a new method to assess breast cancer patients' comorbidity.** *Am J Epidemiol* 2003, **157**:249-257.
97. Fleming ST, Rastogi A, Dmitrienko A and Johnson KD: **A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer.** *Med Care* 1999, **37**:601-614.
98. Buchner DM and Wagner EH: **Preventing frail health.** *Clin Geriatr Med* 1992, **8**:1-17.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

